AVX, a manufacturer and supplier of passive components and interconnect solutions, has released the new MM Series multilayer ceramic capacitors (MLCCs) for medical applications.
Designed for use in medical devices that require significantly less parametric flexibility than commercial capacitors offer, but stop short of demanding the exceptionally stringent features of fully qualified medical capacitors, the new MM Series MLCCs provide medical device manufacturers with extremely consistent, cost-competitive solutions that have the design and change controls necessary to achieve FDA approvals.
To further mitigate the risks already addressed by the defined designs, materials, processes and manufacturing facilities regulated by medical design and change controls, MM Series MLCCs also undergo internal reliability qualification, enhanced lot acceptance testing (LAT), and 100% inspection.
Available in NP0 (C0G) and X7R dielectrics, eight case sizes spanning 0402 to 2220, eight rated voltages spanning 10 to 500 V, and capacitance values spanning 0.5 pF to 1.5 μF, MM Series MLCCs are ideal for use in a wide range of medical devices, aside from those that are both implantable and life supporting, including: implantable, non-life-sustaining medical devices, such as insulin pumps and temporary implantable cardiac monitors; external, life-sustaining medical devices, such as external controllers for heart pumps; and strictly external medical devices, such as patient monitoring and diagnostic equipment.
“Our new MM Series MLCCs provide medical device engineers with exceptional reliability and design flexibility at a competitive price point, eliminating both the inherent risks of using commercial capacitors in these devices and the expense of specifying fully qualified medical capacitors in applications that don’t demand them,” said Lizzie Geismar, product manager, AVX. “As an industry-leading developer and supplier of medical MLCCs, with a long history of providing advanced design, manufacturing, testing, and qualification services for the medical industry, we’re proud to offer our medical customers a new range of products that, through their excellent price/performance ratio, will enable the next-generation of electronic medical devices.”
Unlike commercial MLCCs, MM Series MLCCs for medical applications feature specific series part numbers to control product supply. With regard to design and dicing, MM Series MLCCs have a minimum ceramic thickness of 0.029 in. (versus 0.020 in. for AVX X7R products), 0.004 in. minimum side and end margins (versus 0.003 in.), and cover layers measuring a minimum of 0.003 in.
Additionally, many more MM Series parts are subjected to lot qualification destructive physical analysis (DPA) than are recommended by the EIA RS469 document, and all tested parts are held to significantly stricter criteria.
The series also undergoes 100% inspection for visual and cosmetic quality (versus standard process and inspection), and is not only subjected to increased sampling for accelerated wave solder on X7R and NP0 dielectrics (versus standard sampling for X7R dielectrics), but also subjected to lot-by-lot reliability testing.
Further, as required by medical design and change controls, AVX will qualify and notify customers before making any changes to the following MM Series materials or processes: dielectric, metal and termination material formulation, type or supplier; manufacturing equipment type; and quality testing regime, including sample size and accept/reject criteria, rather than simply informing them should the form, fit or function of the devices change.